News
Why Teva Pharmaceutical Industries, MercadoLibre, and XL Group Jumped Today
The stock market soared on Monday, with major benchmarks finishing higher by 1% or more following a weekend that featured somewhat less devastation than many had feared. Hurricane Irma spent most....
Why Equifax, Regeneron Pharmaceuticals, and AngloGold Ashanti Slumped Today
Monday was a good day for the stock market, with most investors breathing a big sigh of relief despite the devastation that Hurricane Irma caused in the Southeastern U.S. over the weekend. Irma....
Why Teva Pharmaceutical Industries Ltd. (ADR) Is Soaring
After announcing that it has officially filled its vacant CEO seat, Teva Pharmaceutical Industries (NYSE: TEVA), a pharma company primarily focused on generic drugs, jumped 18% as of 1:45 p.m. EDT....
Here's Why Idera Pharmaceuticals, Inc. Is Surging Today
Shares of Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a clinical-stage biotech advancing novel therapies for skin-related diseases, are getting a bump after the company presented trial results at....
Here's Why Allergan Stock Might Be an Incredible Bargain After Dropping 9.9% in August
Despite a stronger-than-expected second quarter earnings report, Allergan's (NYSE: AGN) two month long rally came to an abrupt halt in August with the stock losing 9.9% of its value, according to....
Why Biogen Stock Raced Higher In August
Biotech titan Biogen (NASDAQ: BIIB) saw its shares rise by 8.73% last month, according to data from S&P Global Market Intelligence. This healthy march northward was sparked by an encouraging....
4 Reasons to Buy Intuitive Surgical, Inc. Stock and Never Sell
Before starting, a confession is in order: Over the seven years that I've been a shareholder of Intuitive Surgical (NASDAQ: ISRG), there was a time that I actually sold some of the stock. My....
Allergan's Patent Loophole Could Be a Huge Gift for Pfizer
The tribe has spoken.On Friday, Allergan (NYSE: AGN) announced that the Saint Regis Mohawk Tribe now owns all patents for blockbuster dry-eye disease drug Restatis. Both parties should win from....
Slash Your Medicare Drug Costs With These 6 Tips
IMAGE SOURCE: GETTY IMAGES.If you're one of the millions of Americans with Medicare Part D or Medicare Advantage coverage, or if you're signing up for one of these plans for the first time, then....
3 Reasons to Buy Allergan plc Stock Right Now
Allergan (NYSE: AGN) is one of the most underappreciated big pharma stocks on the market right now. That's the thought that occurred to me as I listened to Brent Saunders, Allergan's CEO, speak at....
Is Amicus Therapeutics Stock Still a Strong Buy?
According to data from S&P Global Market Intelligence, shares of rare-disease drugmaker Amicus Therapeutics (NASDAQ: FOLD) rose by 6.6% last month. Although the company did provide a bevy of....
Why a New Wave of Stock Splits Could Be on the Horizon
Throughout most of the stock market's history, stock splits played a vital role in helping companies control share prices. Recently, though, many companies have stopped doing stock splits even....
Why Exelixis, Inc. Could Be a Gold Mine for Growth Investors
Exelixis (NASDAQ: EXEL) was one of the top biotech stocks of 2016. It's also one of the best biotech stocks so far this year. However, Exelixis shares have pulled back in recent days, primarily....
2 Dividend Stocks You Can Buy and Hold Forever
If you'd like to park your money in stocks and monitor them as little as possible, you need to choose them extra carefully. There's no guarantee that even today's most successful companies won't....
Does Teva's Terrible Tumble Make Its Stock a Buy?
Disappointing financial results, a dividend cut, and reduced guidance have caused Teva Pharmaceutical Industries (NYSE: TEVA) shares to lose half their value in the past month. Can a restructuring....
Is a Med-Tech Marriage in Mazor Robotics' Future?
Medtronic's (NYSE: MDT) salespeople have been generating leads for Mazor Robotics' (NASDAQ: MZOR) robotic surgery system since last year, and recently, the two companies agreed to let Medtronic....
CAR-T Mania: Could Juno Therapeutics Get Acquired Next?
Gilead Sciences (NASDAQ: GILD) recently acquired Kite Pharma (NASDAQ: KITE), but that doesn't mean an acquisition of Juno Therapeutics (NASDAQ: JUNO) is off the table. Juno Therapeutics'....
3 Biotech Stocks That Skyrocketed This Week: Can They Go Higher?
Every biotech company goes into a clinical study with great hopes -- and often great fears, as well. There's no guarantee that all will go well. All the time and money poured into an experimental....
10 Obamacare Tips to Save You Money in 2018
Big changes are coming to the Affordable Care Act (ACA) this fall, which is more commonly known as Obamacare, and they aren't of the variety that's likely to increase enrollment and make the....
2 Big Reasons Exelixis, Inc. Added $626 Million to Its Market Cap in August
Shares of Exelixis (NASDAQ: EXEL), a biotech company primarily focused on developing drugs to treat cancer, rallied more than $2 per share during the month of August, according to data from....
A Perfect Storm Cut Teva Pharmaceutical Industries's Stock in Half in August
Shares of Teva Pharmaceutical Industries (NYSE: TEVA), an Israeli-based developer of branded and generic drugs, imploded in August and lost 51% of its market cap, according to data from S&P....
Better Buy: AbbVie Inc. vs. GlaxoSmithKline plc
Big drugmaker. High dividend yield. Promising new products. All three apply to AbbVie Inc. (NYSE: ABBV). They also all apply to GlaxoSmithKline plc (NYSE: GSK). But while AbbVie stock has achieved....
Good News for Opdivo Shows Why You Shouldn't Give Up on Bristol-Myers Squibb Stock
Bristol-Myers Squibb (NYSE: BMY) investors might have been just a bit worried on Wednesday. After all, the U.S. Food and Drug Administration (FDA) had just placed a partial clinical hold on three....
AbbVie Scores 2 Wins: 1 Threatens Regeneron
AbbVie (NYSE: ABBV) shares are rallying sharply following word that it won a victory against Coherus Biosciences (NASDAQ: CHRS) in a patent challenge and the release of positive late-stage trial....
Are These Healthcare Stocks Top Takeover Targets?
Following Gilead Sciences' (NASDAQ: GILD) decision to buy Kite Pharma (NASDAQ: KITE) for $11.9 billion in cash, we couldn't help but wonder what other healthcare stocks could be takeover targets,....